Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects

BACKGROUND: Parenteral anti-CD3 Mab (OKT3) has been used to treat transplant rejection and parental administration of a humanized anti-CD3 Mab (Teplizumab) showed positive effects in diabetes. Nasal administration of anti-CD3 Mab has not been carried out in humans. Nasal anti-CD3 Mab suppresses auto...

Descripción completa

Detalles Bibliográficos
Autores principales: Chitnis, Tanuja, Kaskow, Belinda J., Case, Junning, Hanus, Katherine, Li, Zhenhua, Varghese, Johnna F., Healy, Brian C., Gauthier, Christian, Saraceno, Taylor J., Saxena, Shrishti, Lokhande, Hrishikesh, Moreira, Thais G., Zurawski, Jonathan, Roditi, Rachel E., Bergmark, Regan W., Giovannoni, Federico, Torti, Maria F., Li, Zhaorong, Quintana, Francisco, Clementi, William A., Shailubhai, Kunwar, Weiner, Howard L., Baecher-Allan, Clare M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727230/
https://www.ncbi.nlm.nih.gov/pubmed/36505477
http://dx.doi.org/10.3389/fimmu.2022.956907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727230/
https://www.ncbi.nlm.nih.gov/pubmed/36505477
http://dx.doi.org/10.3389/fimmu.2022.956907

Ejemplares similares